Previous 10 | Next 10 |
home / stock / atbpf / atbpf news
Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV: ATE, OTCQB: ATBPF) filed its financial and operating results on Friday, July 24 for the fourth quarter and the year ended March 31, 2020. The Company's audited 2020 consolidated financial statements, MD&A and AIF ar...
Toronto, Ontario--(Newsfile Corp. - June 30, 2020) - Antibe Therapeutics Inc. (TSXV: ATE) (" Antibe " or the " Company ") announced that it closed its previously announced bought deal public offering of 62,500,000 units of the Company (the " Units ") at a price of $0.40 per Unit (the " Offerin...
Antibe Therapeutics ( OTCQB:ATBPF ) inks an agreement with a syndicate of underwriters under which they have agreed to purchase 62.5M units at $0.40 per unit yielding gross proceeds of $25M. More news on: Antibe Therapeutics Inc., Healthcare stocks news, , Stocks on the move, Read mo...
Introduction On Monday, June 1, Antibe Therapeutics (ATBPF) announced the positive top-line data from the phase 2B dose-ranging, efficacy study of their lead drug candidate ATB-346. The news was met with an early but short-lived enthusiasm (to daily high of C$0.89, up 16%) and then clo...
Antibe Therapeutics Inc. (TSXV: ATE, OTCQB: ATBPF) will host a conference call Thursday, June 4 at 10:00 am ET to discuss the recent positive results of the Phase 2B dose-ranging, efficacy study for ATB-346. Management will provide a brief summary of the results followed by a Q&A session ...
The News For anyone who is new to the story of Antibe Therapeutics (OTCQB: OTCQB:ATBPF ), here is the SA news item that summarizes the announcement : From a quick reading, the price action seems odd, given that the data appears positive. Was the sell-off simply 'sell-on-the-news'...
Thinly traded micro cap Antibe Therapeutics ( OTCQB:ATBPF -25.2% ) slumps on a 9x surge in volume on the heels of topline data from a Phase 2 clinical trial evaluating lead candidate ATB-346 for the treatment of pain associated with osteoarthritis of the knee. More news on: Anti...
- ATB-346 demonstrates superiority to placebo in reducing osteoarthritis pain - - ATB-346 is more potent than expected; lowest effective dose still to be established - - Antibe plans pivotal Phase 2/3 adaptive registration trial - Antibe Ther...
- Dr. Joseph Stauffer, an anesthesiologist with deep clinical and regulatory experience, fills a key position as Antibe prepares for late-stage development and partnering - Antibe Therapeutics Inc. (TSXV: ATE, OTCQB: ATBPF) is pleased to announce the hiring of Dr. Joseph Stauffer in ...
- Top-line data expected within six weeks - Antibe Therapeutics Inc. (TSXV: ATE, OTCQB: ATBPF) today provides an update on the timing of top-line results for the Phase 2B dose-ranging, efficacy study for its lead drug, ATB-346. Involving 360 patients across 40 clinical sites, this st...
News, Short Squeeze, Breakout and More Instantly...
Biomerieux (BMXMF) is expected to report for Q1 2024 Conn's Inc. (CONN) is expected to report $-0.65 for Q1 2025 Cognetivity Neurosciences Ltd (CGNSF) is expected to report for quarter end 2024-04-30 Aridis Pharmaceuticals Inc. (ARDS) is expected to report for Q1 2024 China Jo-Jo ...
Antibe Therapeutics Inc. (“ Antibe ” or the “ Company ”) (TSX: ATE, OTCQX: ATBPF) announced that its previously announced application for an Initial Order under the Companies' Creditors Arrangement Act (the " CCAA "), has been granted by the Ontario Sup...
Antibe Therapeutics Inc. (“ Antibe ” or the “ Company ”) (TSX: ATE, OTCQX: ATBPF) announced that it intends to file an application today with the Ontario Superior Court of Justice (Commercial List) (the " Court ") for an Initial Order under the Companies'...